The Markey's 8th Annual Review of Hematology and Immunotherapy is a comprehensive educational program designed to translate key scientific advances and clinical updates presented at the American Society of Hematology (ASH) Annual Meeting into practical, evidence-based care. Hosted by University of Kentucky, this symposium provides clinicians with a curated review of the most impactful research, guidelines, and emerging therapies across the spectrum of benign and malignant hematology.

Expert faculty will highlight practice changing abstracts, novel therapeutic strategies, and evolving standards of care in areas including hematologic malignancies, thrombosis and hemostasis, bone marrow failure syndromes, and transfusion medicine. Emphasis is placed on clinical applicability, multidisciplinary decision-making, and integration of new data into patient-centered care within academic and community practice settings.

This program is intended for hematologists, oncologists, advanced practice providers, trainees, pharmacists, nurses, and other healthcare professionals involved in the care of patients with hematologic disorders. Through case-based discussions and expert commentary, participants will enhance their knowledge of recent advances and gain practical insights to improve clinical outcomes.

Target Audience

Hematology/BMT Faculty, APPs, Nurses, Research coordinators and staff, Pharmacist,

Learning Objectives

Upon completion of this activity, participants will be able to:
1. Summarize key clinical and scientific advances presented at the American Society of Hematology (ASH) Annual Meeting that impact the management of malignant and benign hematologic disorders.
2. Review new evidence from pivotal clinical trials and updated guidelines to inform risk stratification, diagnostic evaluation, and treatment selection in hematology practice.
3. Apply emerging therapeutic strategies, including novel agents and combination regimens, to individualized patient care using case-based decision-making.
4. Integrate recent ASH data into multidisciplinary care models while considering patient-specific factors such as comorbidities, treatment tolerability, and health equity.
5. Identify areas of ongoing uncertainty and future research directions in hematology to support continuous learning and quality improvement.

Course summary

Available credit:

6.50 ABS Accredited CME
This activity has been approved for AMA PRA Category 1 Credit™ and meets the American Board of Surgery (ABS) Continuous Certification Program requirements. This activity contributes to the 6.50 CME credit requirement for ABS diplomates. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
6.50 ACPE
In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.
This knowledge-based activity will award 6.50 contact hour(s) (0.100 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers. Course JA-UAN Number: JA0000312-0000-26-015-L01-P
6.50 AMA PRA Category 1 Credit™
In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.
This Live activity is designated for a maximum of 6.50 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
6.50 AMA PRA Category 1 Credit™ Participation
In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.
This Live activity is designated for a maximum of 6.50 AMA PRA Category 1 Credit™ Participation. Learners should claim only credit commensurate with the extent of their participation in the activity.
6.50 ANCC (UK Healthcare CECentral)
In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.
The maximum number of hours awarded for this Continuing Nursing Education activity is 6.50 nursing contact hour(s).
6.50 IPCE
In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 6.50 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.

Course opens:

01/30/2026

Course expires:

05/19/2026

Event starts:

03/21/2026 - 7:30am EDT

Event ends:

03/21/2026 - 4:00pm EDT

Cost:

$1.00

Add to calendar:

8th Annual Review on Hematology and Immunotherapy
From the December 2025 Annual Meeting of the American Society of Hematology
March 21, 2026 – Central Bank Center

Agenda

7:30 a.m. – 8:00 a.m.
Registration and Breakfast

8:00 a.m. – 8:05 a.m.
Welcome
Mark Evers, Director, Markey Cancer Center

8:05 a.m. – 8:15 a.m.
Opening Remarks and Outline of the Day
Pierluigi Porcu, MD; Ewa Marciniak, MD, Endowed Chair of Medicine; Professor and Division Chief, Hematology and Cellular Therapy; University of Kentucky

Session I (Moderator: Dr. Iragavarapu)

8:15 a.m. – 9:00 a.m.
Keynote Speaker I
Updates in Cellular Therapy
Michael R. Bishop, MD; Professor of Medicine; Director, The David and Etta Jonas Center for Cellular Therapy; University of Chicago

9:00 a.m. – 9:30 a.m.
T-cell Lymphomas
Pierluigi Porcu, MD; Ewa Marciniak, MD, Endowed Chair of Medicine; Professor and Division Chief, Hematology and Cellular Therapy

9:30 a.m. – 10:20 a.m.
Keynote Speaker II
Updates in Aggressive B-cell Lymphoma
David Qualls, MD; Instructor in Medicine, Harvard Medical School, Dana-Farber Cancer Institute

10:20 a.m. – 10:45 a.m.
Break / Exhibits

Session II (Moderator: Dr. Qasrawi)

10:45 a.m. – 11:15 a.m.
Low Grade Lymphomas and Chronic Lymphocytic Leukemia
Hiffsa Taj, MD; Assistant Professor, Hematology and Cellular Therapy; University of Kentucky

11:15 a.m. – 12:00 p.m.
Keynote Speaker III
Updates in Multiple Myeloma
Bhagirathbhai Dholaria, MD, FACP; Associate Professor, Department of Medicine, Hematology and Oncology; Vanderbilt University

12:00 p.m. – 12:30 p.m.
New Immunotherapies in Plasma Cell Dyscrasia
Greg Monohan, MD; Professor, Hematology and Cellular Therapy; University of Kentucky

12:30 p.m. – 1:30 p.m.
Lunch / Exhibit

Session III (Moderator: Dr. Monohan)

1:30 p.m. – 2:15 p.m.
Keynote Speaker IV
Updates in Classical Hematology: Bleeding, Thrombosis, and Sickle Cell Disease
Vlad Călin Rădulescu, MD; Professor of Pediatrics; Director, Hemophilia Treatment Center; University of Kentucky

2:15 p.m. – 2:45 p.m.
Acute Myeloid Leukemia Updates
Fevzi Yalniz, MD; Assistant Professor, Hematology and Cellular Therapy; University of Kentucky

2:45 p.m. – 3:00 p.m.
Break / Coffee

3:00 p.m. – 3:30 p.m.
Updates in Palliative Care – TBD
Jessica M. McFarlin, MD; Division Chief, Palliative and Supportive Care; University of Kentucky

3:30 p.m. – 4:00 p.m.
Pharmacy Updates – TBD
Bryant A. Clemons, PharmD; Hematology and Cellular Therapy; University of Kentucky

4:00 p.m. – 4:05 p.m.
Closing Remarks and Evaluations
Pierluigi Porcu, MD; Professor and Division Chief, University of Kentucky, Division of Hematology/BMT

Central Bank Center

430 W Vine St

Lexington, KY 40507

United States

+1 (859) 233-4567

https://www.centralbankcenter.com/

Moderator(s)

Chait Iragavarapu, Assistant Professor of Medicine

has a financial relationship (Grant Or Contract) with Jannsen;.

has a financial relationship (Grant Or Contract) with Merck;.

has a financial relationship (Grant Or Contract) with Kite/Gilead;.

has a financial relationship (Grant Or Contract) with Century Therapeutics;.

has a financial relationship (Grant Or Contract) with Regeneron;.

has a financial relationship (Grant Or Contract) with Morphosys/Incyte;.

has a financial relationship (Grant Or Contract) with Celgene/BMS;.

has a financial relationship (Grant Or Contract) with Abbvie;.

Gregory Monohan, MD

has a financial relationship (Stock) with Quest Diagnostics;.

has a financial relationship (Stock) with Johnson & Johnson;.

has a financial relationship (Stock) with Novartis;.

has a financial relationship (Stock) with Pfizer;.

has a financial relationship (Stock) with DuPont;.

Planner(s)

Natalie Hawes, RN, BSN, CCRP

has no relevant financial relationships to disclose at this time.